Aegerion Pharmaceuticals, Inc.
Cardiovascular Drug Development Company
Website
www.aegerion.com
Contact Name
Mr. Will Lewis
Company Position
Senior Vice President & Chief Financial Officer
Contact Email
info@aegerion.com
Contact Address
CenterPointe IV
1140 Route 22 East, Suite 304
Bridgewater
NJ 08807
USA
Contact Phone
+1 908 704 1300
Latest News
16th November 2009
Aegerion Pharmaceuticals, Inc., has announced very promising additional data from its ongoing Phase III trial of lomitapide
Read this article
More News
21st March 2007
Aegerion Pharmaceuticals, Inc. has filed with regulators to raise up to $86.25million in an initial public offering.
Read this article
10th January 2007
Aegerion Pharmaceuticals, Inc. which focuses on the treatment of cardiovascular and metabolic diseases, announces positive results from a second Phase II clinical trial of its lead cholesterol-lowering compound AEGR-733.
Read this article
15th November 2006
Aegerion Pharmaceuticals, Inc. has announced interim results from its phase II clinical trial involving its lead cholesterol management compound, AEGR-733, alone and in combination with Zetia ®.
Read this article
Aegerion Pharmaceuticals, Inc. is a speciality pharamceutical company focused on the development and commercialisation of pharmaceuticals to treat cardiovascular (CV) and metabolic disease.
Aegerion's initial emphasis is on hyperlipidemia and its lead products are microsomal triglyceride transfer protein (MTP) inhibitors that have demonstrated significant LDL lowering activity in man. This class of compound possesses a dual-mechanism of action influencing the production of VLDL in the liver and chylomicrons in the intestine which represent the packaging and transport of cholesterol and triglycerides in the body and are the precursors to atherogenic particles, such as LDL. Aegerion's compounds may address patient populations predisposed genetically to have very high levels of LDL; recently, Aegerion's drugs may also have a place in treating obesity.
Cholesterol lowering therapeutics represents one of the largest markets in the pharmaceutical industry, with annual worldwide revenues of approximately $28 billion.
